New Lawsuit Alleges Zoloft No Better Than Placebo; Personal Injury Lawyer Jeff Nadrich Responds

Share Article

Pfizer, the manufacturer of antidepressant Zoloft, is accused of withholding research that sheds a negative light on the drug. Personal injury lawyer Jeff Nadrich responds.

Pfizer, the maker of the popular antidepressant Zoloft, is being sued by a plaintiff who claims that the drug is no better than a placebo, the Associated Press reports. The case (13-CV-00414-PSG) is being tried in the United States District Court for the Northern District of California, San Jose Division, before Magistrate Judge Paul Singh Grewal.

The AP reports that the plaintiff, Laura A. Plumlee, claims to have taken Zoloft for three years, and that the drug had no noticeable impact on her depression. Plumlee’s attorney further argues that the Food and Drug Administration should never have approved Zoloft because Pfizer withheld clinical studies that found the drug about as effective as a placebo.

“It’s about Pfizer deliberately withholding this information from consumers and then advertising this drug as very effective,” Wisner told the AP.

Pfizer, however, denies the charges. “Pfizer believes the lawsuit filed in California is groundless and is based largely on information ... that has been widely criticized by many experts in the mental health field,” the company said in a statement provided to the Associated Press.

Zoloft has already been subject to controversy after the FDA warned of possible birth defects associated with use of the drug. Jeff Nadrich, a personal injury lawyer and drug defect attorney based in Los Angeles, has been concerned with the serious side effects of Zoloft for years, and recently weighed in about the new development on his blog.

According to Nadrich, “The allegations here are alarming. Zoloft has more than 37 million users in the U.S. alone, and has already proven highly controversial due to birth defects, suicides and overdoses. If it’s true that Pfizer neglected to inform the FDA about clinical trials proving ineffectiveness, the FDA should take immediate action against the manufacturer.”

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeff Nadrich
Nadrich & Cohen LLP
Email >
Visit website